Search

Displaying results 2011 - 2020 of 5263 in total
  1. Drug

    Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10291
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 19F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from

  2. Drug

    Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10292
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 23F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from

  3. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.

  4. Drug

    Methoxyflurane

    go.drugbank.com/drugs/DB01028
    ApprovedInvestigationalVet approvedWithdrawn

    (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]

  5. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. … [L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease.

  6. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual

  7. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag binds to the transmembrane domain of TPOR expressed on megakaryocytes, and causes the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells [FDA

  8. Drug

    Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16711
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 33F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from

  9. Drug

    Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10287
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 6b individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from

  10. Drug

    Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10288
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 9v individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from